Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
Key Highlights
- ➤Zentalis management to join Guggenheim healthcare conference November 10, 2026
- ➤Zentalis presentation scheduled for Stifel Healthcare Conference November 11, 2026
- ➤Azenosertib advances late-stage development as an investigational WEE1 inhibitor
- ➤Zentalis is developing ovarian cancer treatments and multiple tumor types
Expert Statements
Aron Feingold, VP, Investor Relations & Corporate Communications at Zentalis Pharmaceuticals
“No direct quote provided in the article.”
SAN DIEGO, Nov. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis(®) Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in the following upcoming investor conferences: * Guggenheim's 3rd Annual Healthcare Innovation Conference, Boston, MA. Fireside discussion, November 10, 2026, 2:00 p.m. ET.
* Stifel 2026 Healthcare Conference, New York, NY. Company presentation, November 11, 2026, 4:00 p.m. ET. Access to a live webcast of each of the Guggenheim and Stifel events, as well as an archived recording, will be available under the “Events & Presentations” tab on the Investors & Media section of the Company’s website.
Get started
Create a free account to read the full story.